CDC panel wants more data before deciding whether to resume use of Johnson & Johnson vaccine

An illustration showing Johnson & Johnson vaccines.
(Image credit: JUSTIN TALLIS/AFP via Getty Images)

A Centers for Disease Control and Prevention advisory panel decided in an emergency meeting on Wednesday that members need more data before voting on how to proceed with Johnson & Johnson's one-dose COVID-19 vaccine.

On Tuesday, the CDC and Federal Drug Administration recommended a pause in using the Johnson & Johnson vaccine after six women who received it developed rare brain blood clots. One of the women died. The panel is seeking more information on the clots, including the risk factors and frequency, and will reconvene in the next seven to 10 days.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Catherine Garcia, The Week US

Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.